I am a health economics PhD candidate at the Erasmus School of Health Policy & Management in Rotterdam and hold a master degree in health economics (University of Bayreuth and UNC Chapel Hill). I am also part of a European PhD training network (Improving Quality of Care in Europe), and am funded through a Marie-Curie fellowship, awarded by the European Commission.
In my doctorate, I am applying economic and statistical tools, including applied econometrics, health economic modelling, and discrete choice experiments, to conduct research on topics surrounding tools to inform the efficient allocation of health care resources. This especially includes eliciting preferences on the importance of different (health-related) quality of life dimensions and obtaining societal monetary valuations of health and well-being gains. Further research interests include the measurement of well-being, fair pricing of pharmaceuticals, and patient and provider preferences in mental health care.
Download my resumé.
M.Sc. in Health Economics, 2016
University of Bayreuth, University of North Carolina at Chapel Hill
B.Sc. in Health Economics, 2013
University of Bayreuth
Electronic health interventions especially for mental health may more and more provide valuable treatment possibilities. This paper attempted to measure preferences in the general German population and mental health users towards different attributes of potential electronic heath interventions, finding that blended care formats (i.e. a combination in-person and electronic means) would be most preferred.
As a pre-study for generating population weights for a nine-dimensional well-being instrument among the eldery, we examined which type of choice experiment is less cognitively burdensome to survey respondents.
We used a dataset originally collected for a different purpose to estimate the monetary value of health and capability well-being based on the well-being valuation approach.
In this first paper of my PhD project, we used an alternatve approach to estimate utility weights for two capability well-being instruments (ICECAP-A and ICECAP-O).
This paper tries to answer the question on how much European citizens would be willing to pay for an early warning system for infectious diseases. It was part of the COMPARE project and unfortunately is now way more topcial then anticipated when the study was conducted.
In this project, we quantified the societal economic impact of the use of a novel biologic treatment for ankolysing spondylitis in Germany.
This study quantifies the productivity gains associated with the use of obinutuzumab in follicular lymphoma patients, including gains in paid work and in unpaid work
We estimated the societal impact of the use of a biologic treatment for psoriatic arthritis in Germany for the years 2016 to 2030.
In this project, we aggregated the societal health effects of the use of a novel anticoagulant in patients with atrial fibrillation.